October 26, 2017 08:52 AM EDT
R&D

Ab­b­Vie boasts a PhI­II sweep for top pso­ri­a­sis con­tender risankizum­ab, but it has lots of com­pe­ti­tion

John Carroll

Editor & Founder

Ab­b­Vie paid Boehringer $595 mil­lion up­front to li­cense rights to risankizum­ab in ear­ly 2016, and this morn­ing the com­pa­ny dis­played a late-stage dataset on pso­ri­a­sis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times